Limited reliability of H3K27M detection using a commercially available blood-based comprehensive genomic profiling test in patients with diffuse midline gliomas: analysis of the nationwide C-CAT database in Japan.

Abstract excerpt

BACKGROUND: This study aimed to assess the ability of FoundationOne Liquid CDx (F1 Liquid), a blood-based comprehensive genomic profiling test introduced in Japan in 2021, to detect the H3K27M mutation in patients with diffuse midline glioma using a nationwide real-world database in Japan. METHODS: We identified patients with IDH-wildtype diffuse gliomas in midline locations registered in the Center for Cancer...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Neoplasms
• Share to Child